Overview

Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance

Status:
Unknown status

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

Summary

Chronic hepatitis C virus (HCV) infection is associated with an increased risk for the development of type 2 diabetes and HCV infection itself may promote insulin resistance, irrespective of the severity of liver disease. Insulin resistance seems to be genotype specific and may play a role in fibrogenesis in chronic hepatitis C. In an "in vitro" model, increased levels of insulin may promote increased HCV replication. RATIONALE Decreased insulin resistance and reduced hyperinsulinemia may facilitate the efficacy of anti-viral drugs on HCV replication.

Phase:

Phase 4

Details

Lead Sponsor:

University of Turin, Italy

Treatments:

Insulin
Interferons
Metformin
Ribavirin